Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Oxysterols in cancer management: From therapy to biomarkers

A. Kloudova-Spalenkova, P. Holy, P. Soucek

. 2021 ; 178 (16) : 3235-3247. [pub] 20201018

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025184

Grantová podpora
NV17-28470A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK Free Medical Journals od 1968 do Před 1 rokem
Europe PubMed Central od 1968 do Před 1 rokem
Medline Complete (EBSCOhost) od 2002-01-01 do Před 1 rokem
Wiley Free Content od 1997

Oxysterols are oxidized derivatives of cholesterol, both endogenous and exogenous. They have been implicated in numerous pathologies, including cancer. In addition to their roles in carcinogenesis, proliferation, migration, apoptosis, and multiple signalling pathways, they have been shown to modulate cancer therapy. They are known to affect therapy of hormonally positive breast cancer through modulating oestrogen receptor activity. Oxysterols have also been shown in various in vitro models to influence efficacy of chemotherapeutics, such as doxorubicin, vincristine, cisplatin, 5-fluorouracil, and others. Their effects on the immune system should also be considered in immunotherapy. Selective anti-cancer cytotoxic properties of some oxysterols make them candidates for new therapeutic molecules. Finally, differences in oxysterol levels in blood of cancer patients in different stages or versus healthy controls, and in tumour versus non-tumour tissues, show potential of oxysterols as biomarkers for cancer management and patient stratification for optimization of therapy. LINKED ARTICLES: This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025184
003      
CZ-PrNML
005      
20211026134039.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bph.15273 $2 doi
035    __
$a (PubMed)32986851
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kloudova-Spalenkova, Alzbeta $u Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Oxysterols in cancer management: From therapy to biomarkers / $c A. Kloudova-Spalenkova, P. Holy, P. Soucek
520    9_
$a Oxysterols are oxidized derivatives of cholesterol, both endogenous and exogenous. They have been implicated in numerous pathologies, including cancer. In addition to their roles in carcinogenesis, proliferation, migration, apoptosis, and multiple signalling pathways, they have been shown to modulate cancer therapy. They are known to affect therapy of hormonally positive breast cancer through modulating oestrogen receptor activity. Oxysterols have also been shown in various in vitro models to influence efficacy of chemotherapeutics, such as doxorubicin, vincristine, cisplatin, 5-fluorouracil, and others. Their effects on the immune system should also be considered in immunotherapy. Selective anti-cancer cytotoxic properties of some oxysterols make them candidates for new therapeutic molecules. Finally, differences in oxysterol levels in blood of cancer patients in different stages or versus healthy controls, and in tumour versus non-tumour tissues, show potential of oxysterols as biomarkers for cancer management and patient stratification for optimization of therapy. LINKED ARTICLES: This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc.
650    _2
$a biologické markery $7 D015415
650    _2
$a lidé $7 D006801
650    _2
$a imunitní systém $7 D007107
650    _2
$a imunoterapie $7 D007167
650    12
$a nádory $x farmakoterapie $7 D009369
650    12
$a oxysteroly $7 D000072376
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Holy, Petr $u Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Soucek, Pavel $u Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 178, č. 16 (2021), s. 3235-3247
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32986851 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134045 $b ABA008
999    __
$a ok $b bmc $g 1714300 $s 1145691
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 178 $c 16 $d 3235-3247 $e 20201018 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
GRA    __
$a NV17-28470A $p MZ0
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...